Keywords: nz, fund, merck, co/, s-p, cholesterol, drugs
NZ to fund Merck & Co/ S-P cholesterol drugs
Article | 21 June 2004
PHARMAC, New Zealand's pharmaceutical management agency, has said the cholesterol-lowerer Ezetrol (ezetimibe), marketed by the Merck & Co/Schering-Plough company MSP ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
